American Cancer Society:Cancer facts & figures.Atlanta, Ga, American Cancer Society, 2000.
2.
LymanG.H.: Cancer care in the elderly.Cancer Control, 5: 347–354, 1998.
3.
RepettoL., VenturinoA., VercelliM., GianniW., Bian-cardiV., CasellaC., GranettoC., ParodiS., RossoR., MariglianoV.: Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions.Cancer, 82: 760–765, 1998.
4.
LandefeldC.S., PalmerR.M., KresevicD.M., FortinskyR.H., KowalJ.: A randomized trial of care in a hospital medical unit especially designed to improve the functional outcomes of acutely ill older patients.N Engl J Med, 332: 1338–1344, 1995.
5.
CounsellS.R., HolderC.M., LiebenauerL.L., PalmerR.M., FortinskyR.H., KresevicD.M., QuinnL.M., AllenK.R., CovinskyK.E., LandefeldC.S.: Effects of a multicom-ponent intervention on functional outcomes and process of care in hospitalized older patients: a randomized controlled trial of acute care for elders (ACE) in a community hospital.J Am Geriatr Soc, 48: 1572–1581, 2000.
6.
GivenB., GivenC., AzzouzF., StommelM.: Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment.Nurs Res, 50: 222–232, 2001.
7.
GivenC.W., GivenB., AzzouzF., StommelM., KozachikS.: Comparison of changes in physical functioning of elderly patients with new diagnoses of cancer.Med Care, 38: 482–493, 2000.
8.
IngramS.S., SeoP.H., MartellR.E., ClippE.C., DoyleM.E., MontanaG.S., CohenH.J.: Comprehensive assessment of the elderly cancer patient: the feasibility of self-report methodology.J Clin Oncol, 20: 770–775, 2002.
9.
SerrainoD., FratinoL., ZagonelV.: Prevalence of functional disability among elderly patients with cancer.Crit Rev Oncol Hematol, 39: 269–273, 2001.
10.
RepettoL., VenturinoA., FratinoL., SerrainoD., TroisiG., GianniW., PietropaoloM.: Geriatric oncology: a clinical approach to the older patient with cancer.EJC, 39: 870–880, 2003.
11.
FerrucciL., GuralnikJ.M., CavazziniC., BandinelliS., RepettoL., LongoD.L.: The frailty syndrome: a critical issue in geriatric oncology.CROH, in press.
12.
FriedL.P., TangenC.M., WalstonJ., NewmanA. B., HirschC., GottdienerJ., SeemanT., TracyR., KopW.J., BurkeG., McBurnieM.A.: Frailty in older adults: evidence for a phenotype.J Gerontol A Biol Sci Med Sci, 56: M146–M156, 2001.
13.
MonfardiniS., FerrucciL., FratinoL., Del LungoI., SerrainoD., ZagonelV.: Validation of a multidimensional evaluation scale for use in elderly cancer patients.Cancer, 77: 395–401, 1996.
14.
RepettoL., FratinoL., AudisioR.A., VenturinoA., GianniW, VercelliM., ParodiS.: The comprehensive geriatric assessment adds information to ECOG performance status in elderly cancer patients: a GIOGer study.J Clin Oncol, 20: 494–502, 2002.
15.
SargentD., GoldbergR., JacobsonS.D., MacDonaldJ.S., LabiancaR.: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.N Engl J Med, 345: 1091–1097, 2001.
16.
LangerC.J., ManolaJ., BernardoP., KuglerJ.W., Bono-miP., CellaD., JohnsonD.H.: Cisplatin based therapy for elderly patients with advanced non-small cell lung cancer: implication of Eastern Cooperative Oncology Group 5592, a randomised trial.J Natl Cancer Inst, 94: 173–181, 2002.
17.
CovaD., BerettaG., CalducciL.: Cancer chemotherapy in the older patient. In: BalducciL., LymanG.H., ErshlerW.B., Comprehensive geriatric oncology.Hardwood Academic Publishers, London, pp 429–442, 1998.
18.
Iwashyna, et al: Survival benefit from 5-FU in elderly stage III colon cancer patients.J Clin Oncol, 20: 3992, 2002.
19.
NeugutElderly stage III rectal cancer patients benefit from 5-FU + RT.J Clin Oncol, 20: 2643, 2002.
20.
MagneN., FrancoisE., BroisinL., GuardiolaE., Ra-maioliA., FerreroJ.M., NamerM.: Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-year experience.Am J Clin Oncol, 25: 126–130, 2002.
21.
ChenH., CantorA., MeyerJ., Beth CorcoranM., GrendysE., CavanaughD., AntonekS., CamarataA., HaleyW., BalducciL., ExtermannM.: Can older cancer patients tolerate chemotherapy? A prospective pilot study.Cancer, 97: 1107–1114, 2003.
22.
ExtermannM., AlbrandG.: Are older French patients as willing as older American patients to underwent chemotherapy?J Clin Oncol, 21: 3214–3219, 2003.
23.
EdnaT.H., BjerkesetT.: Colorectal cancer in patients over 80 years of age.Hepatogastroenterology, 45: 2142–2145, 1998.
24.
MakelaJ.T., KiviniemiH., LaitinenS.: Survival after operations for colorectal cancer in patients aged 75 years or over.Eur J Surg, 166: 473–479, 2000.
25.
Colorectal Cancer Collaborative Group:Surgery for colorectal cancer in the elderly patients: a systematic review.Lancet, 356: 968–974, 2000.
26.
KarlR.C., SmithS.K., FabriP.J.: Validity of major operations in elderly patients.Ann Surg Oncol, 2: 107–113, 1995.
27.
HealdR.J., MoranB.J., RyallR.D.: Rectal cancer. The basingstoke experience of total mesorectal excision, 1978-1997.Arch Surg, 133: 894–891, 998.
28.
Tabah-FishI., Maindrault-GoebelF., BenavidesM.: Oxaliplatin/5-FU/LV is feasible, safe and active in elderly colorectal cancer patients.Proc ASCO, 21: 556 (abst), 2002.
29.
FortnerJ.G., LincerR.M.: Hepatic resection in the elderly.Ann Surg, 211: 141–146, 1990.
30.
FongY., BlumgartL.H., FortnerJ.G., BrennanM.F.: Pancreatic or liver resection for malignancy is safe and effective for the elderly.Ann Surg, 4: 426–437, 1995.
31.
Colorectal Cancer Collaborative Group: Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis.BMJ, 321: 531–535, 2000.
32.
SaltzL.B., CoxJ.V., BlankeC.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.N Engl J Med, 343: 905–914, 2000.
33.
DouillardJ.Y., CunnimghamD., RothA.D.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer. A multicentre randomised trial.Lancet, 355: 1041–1047, 2000.
34.
GiacchettiS., PerpointB., ZidaniR.Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.J Clin Oncol, 18: 136–147, 2000.
35.
De GramontA., FigerA., SeymourM.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.J Clin Oncol;18: 2938–2947, 2000.
36.
SchaafL.B., IcchpuraniN., ElfringG.L.: Influence of age on the pharmacokinetics of irinotecan and its metabolites, SN-38 and SN-38 glucuronide, in patients with previously treated colorectal cancer.Proc ASCO, 16: 202A (abst), 1998.
37.
GiacchettiS., RaymondE., ChaneyS.G., TaammaA.: Oxaliplatin: a review of preclinical and clinical studies.Ann Oncol, 9: 1053–1071, 1998.
38.
Diaz-RubioE., SastreJ., AbadA.: UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients.Oncology, 13: 35–40, 1999.
39.
FeliuJ., Gonzalez BaronM., EspinosaE.: Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Collaborative Group.Cancer, 79: 1884–1889, 1997.
40.
Van CutsemE., TwelvesC., CassidyJ.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.J Clin Oncol, 21: 4097–4106, 2001.
41.
PopescuR.A., NormanA., RossP.J.: Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.J Clin Oncol, 17: 2412–2422, 1999.
IyerL., RatainM.J.: Clinical pharmacology of cam-pothecins.Cancer Chemoter Pharmacol,42(suppl): S31–S43.
44.
KleinC.E., GuptaE., ReidJ.M.: Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.Clin Pharmacol Ther, 72: 638–647, 2002.
45.
RougierP., MitryE., CunninghamD.: Is age a prognostic factor of toxicity and efficacy in patients (pts) with metastatic colorectal cancer (MCRC) receiving irinotecan in combination with 5FU/folinic acid (FA)?Proc ASCO,22: abst 1072, 2003.
46.
MitryE., DouillardJ.Y., van CutsemE.: Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trial.Ann Oncol, 15: 1013–1017, 2004.
47.
RougierP., Van CutsemE., BajettaE.: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.Lancet, 352: 1407–1412, 1998.
48.
SaltzL.B.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.N Engl J Med, 343: 905–914, 2000.
